Stay informed with the latest litigation news. Explore now
Novel Modified Release Dosage Forms Of Xanthine Oxidoreductase Inhibitor Or Xanthine Oxidase Inhibitors - EP2582812B1
EP2582812
- Application Number
- EP11796331A
- Filing Date
- Jun 15, 2011
- Status
- No Opposition Filed Within Time Limit
- Nov 30, 2018
- Grant Date
- Jan 24, 2018
- External Links
- Slate, Register, Google Patents
Bibliography
The patent EP2582812B1 was granted to Takeda Pharmaceuticals USA on Jan 24, 2018 following the initial filing on Jun 15, 2011 under the application number EP11796331A . The current legal status of the patent is No Opposition Filed Within Time Limit.
Patent Summary
Patent Family New
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Date
Description
Get instant alerts for new documents